This morning many investors are going to be looking into those stocks which managed to clock substantial gains on Thursday and one of the stocks which could be in focus is of Interpace Biosciences Inc (OTCMKTS:IDXG).
Trading Data
On Thursday, IDXG stock jumped 25% to $2.2500 with more than 40.69K shares, compared to its average volume of 4.36K shares. The stock moved within a range of $1.6150 – 2.4800 after opening trade at $1.6150.
Interpace Biosciences Announces New Clinical Validation Data; Diagnostic Accuracy Significantly Improved
The molecular diagnostics tests and pathology company saw its stock clock gains of as much as 25% after it made a major announcement with regards to one of its latest projects. The company announced fresh validation data with regard to its thyroid cancer test platform. The platform in question consists of a mutation panel in addition to a microRNA risk classifier. The new data demonstrated that the addition of microRNA risk classifier led to improved results.
It was a major new development for the company and one that could lead to a long-term boost in its diagnostic business. The data also revealed that the platform demonstrated considerable improvement in discovering the number of true negative results and on top of that the number of false positive results was also reduced.
It is now going to be interesting to see if the Interpace stock manages to hold on to its momentum and clocks further gains in the coming days.
Key Quote
Dr. Syd Finkelstein, Chief Scientific Officer of Interpace Diagnostics, commented that “miRNA analysis may also reduce the risk of RNA sampling error because miRNAs can migrate throughout the thyroid nodule. As a result, they may be less affected by spatial variability than the distribution of cells with DNA mutations.“
Technical Data
IDXG stock is trading below the 20-Day and 50-Day Moving averages of $2.11 and $2.56 respectively. Moreover, the stock is trading below the 200-Day moving average of $4.68. The company has a total market capitalization of $9 million. The stock is down 12% over the past month.
